Webinar: Rare access, the varying pace of change Event report

Industry experts attended the PM Society’s webinar on the 8th July to discuss how the UK authorities are performing compared to the rest of Europe when reimbursing and recommending new, innovative therapies. The webinar was hosted by Andrew Mumford, Principal Consultant – Market Access, at Initiate Consultancy, along with Craig Bradley, co-chair of the PM … Continued

UK Market Access 2019 – Event Review

Speaker Bios and Slides   Craig Bradley, Product & Business Lead Rare GI, Takeda Craig has worked for Takeda, via legacy Shire Pharmaceuticals, since July 2006 within a variety of sales, marketing and market access roles. Craig is currently the Product & Business Lead for Rare GI. Craig has over 15 years’ experience within the … Continued

Developing high value partnerships with the NHS

Hassan Chaudhury, is a member of the PM Society Market Access Group and is Chief Commercial Officer and Co-Founder, Health iQ – Leaders in Real World Data Introduction Many life science organisations want to form lasting partnerships with the NHS. It is only natural to set this as a strategic goal since the NHS is … Continued

Patient Access to new medicines; the changing landscape

Introduction The market access landscape has changed substantially since the introduction of NICE (1999) and the PPRS (2009, updated in 2014). Increasingly formalised pricing mechanisms were introduced in the PPRS (2009) to allow a range of options to industry, including patient access schemes. The core focus of NICE at the start of its existence, in … Continued